Key differences:
🔑added JAK inhibitors to bDMARD considerations
🔑specific EMM recs: monoclonal TNFi for uveitis, IBD; IL17i for PsO
🔑consider taper if in sustained remission
@sofiaramiro82@Official_ASAS@eular_org 🌟Abs 0545 Weinstein, et al
phase 4 RCT, golimumab withdrawal in nr-axSpA
n=188
randomized to: continued GOL, reduced GOL q2m, withdrawal